1
|
Tav C, Fournier É, Fournier M, Khadangi F, Baguette A, Côté MC, Silveira MAD, Bérubé-Simard FA, Bourque G, Droit A, Bilodeau S. Glucocorticoid stimulation induces regionalized gene responses within topologically associating domains. Front Genet 2023; 14:1237092. [PMID: 37576549 PMCID: PMC10413275 DOI: 10.3389/fgene.2023.1237092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 07/07/2023] [Indexed: 08/15/2023] Open
Abstract
Transcription-factor binding to cis-regulatory regions regulates the gene expression program of a cell, but occupancy is often a poor predictor of the gene response. Here, we show that glucocorticoid stimulation led to the reorganization of transcriptional coregulators MED1 and BRD4 within topologically associating domains (TADs), resulting in active or repressive gene environments. Indeed, we observed a bias toward the activation or repression of a TAD when their activities were defined by the number of regions gaining and losing MED1 and BRD4 following dexamethasone (Dex) stimulation. Variations in Dex-responsive genes at the RNA levels were consistent with the redistribution of MED1 and BRD4 at the associated cis-regulatory regions. Interestingly, Dex-responsive genes without the differential recruitment of MED1 and BRD4 or binding by the glucocorticoid receptor were found within TADs, which gained or lost MED1 and BRD4, suggesting a role of the surrounding environment in gene regulation. However, the amplitude of the response of Dex-regulated genes was higher when the differential recruitment of the glucocorticoid receptor and transcriptional coregulators was observed, reaffirming the role of transcription factor-driven gene regulation and attributing a lesser role to the TAD environment. These results support a model where a signal-induced transcription factor induces a regionalized effect throughout the TAD, redefining the notion of direct and indirect effects of transcription factors on target genes.
Collapse
Affiliation(s)
- Christophe Tav
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
- Centre de Recherche en Données Massives de l’Université Laval, Québec, QC, Canada
| | - Éric Fournier
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
- Centre de Recherche en Données Massives de l’Université Laval, Québec, QC, Canada
| | - Michèle Fournier
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
| | - Fatemeh Khadangi
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
| | - Audrey Baguette
- Department of Human Genetics, Faculty of Medicine, McGill University, Montréal, QC, Canada
| | - Maxime C. Côté
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
| | - Maruhen A. D. Silveira
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
| | - Félix-Antoine Bérubé-Simard
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
| | - Guillaume Bourque
- Department of Human Genetics, Faculty of Medicine, McGill University, Montréal, QC, Canada
- Canadian Center for Computational Genomics, McGill University, Montréal, QC, Canada
| | - Arnaud Droit
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
- Centre de Recherche en Données Massives de l’Université Laval, Québec, QC, Canada
- Centre de Recherche du CHU de Québec—Université Laval, Axe Endocrinologie et Néphrologie, Québec, QC, Canada
- Département de Médecine Moléculaire, Faculté de Médecine, Université Laval, Québec, QC, Canada
| | - Steve Bilodeau
- Centre de Recherche du CHU de Québec—Université Laval, Axe Oncologie, Québec, QC, Canada
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada
- Centre de Recherche en Données Massives de l’Université Laval, Québec, QC, Canada
- Département de Biologie Moléculaire, Biochimie Médicale et Pathologie, Faculté de Médecine, Université Laval, Québec, QC, Canada
| |
Collapse
|
2
|
Vu MT, Jardani A, Massei N, Deloffre J, Fournier M, Laignel B. Long-run forecasting surface and groundwater dynamics from intermittent observation data: An evaluation for 50 years. Sci Total Environ 2023; 880:163338. [PMID: 37023828 DOI: 10.1016/j.scitotenv.2023.163338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 03/09/2023] [Accepted: 04/03/2023] [Indexed: 05/27/2023]
Abstract
The accurate prediction of water dynamics is critical for operational water resource management. In this study, we propose a novel approach to perform long-term forecasts of daily water dynamics, including river levels, river discharges, and groundwater levels, with a lead time of 7-30 days. The approach is based on the state-of-the-art neural network, bidirectional long short-term memory (BiLSTM), to enhance the accuracy and consistency of dynamic predictions. The operation of this forecasting system relies on an in-situ database observed for over 50 years with records gauging in 19 rivers, the karst aquifer, the English Channel, and the meteorological network in Normandy, France. To address the problem of missing measurements and gauge installations over time, we developed an adaptive scheme in which the neural network is regularly adjusted and re-trained in response to changing inputs during a long operation. Advances in BiLSTM with extensive learning past-to-future and future-to-past further help to avoid time-lag calibration that simplifies data processing. The proposed approach provides high accuracy and consistent prediction for the three water dynamics within a similar accuracy range as an on-site observation, with approximately 3 % error in the measurement range for the 7 day-ahead predictions and 6 % error for the 30 d-ahead predictions. The system also effectively fills the gap in actual measurements and detects anomalies at gauges that can last for years. Working with multiple dynamics not only proves that the data-driven model is a unified approach but also reveals the impact of the physical background of the dynamics on the performance of their predictions. Groundwater undergoes a slow filtration process following a low-frequency fluctuation, favoring long-term prediction, which differs from other higher-frequency river dynamics. The physical nature drives the predictive performance even when using a data-driven model.
Collapse
Affiliation(s)
- M T Vu
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France.
| | - A Jardani
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France
| | - N Massei
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France
| | - J Deloffre
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France
| | - M Fournier
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France
| | - B Laignel
- Université de Rouen, M2C, UMR 6143, CNRS, Morphodynamique Continentale et Côtière, Mont Saint Aignan, France
| |
Collapse
|
3
|
Maurais T, Kriese J, Fournier M, Langevin L, MacLeod B, Blier S, Tessier-Guay JP, Girardin A, Maheux L. Effectiveness of Selected Air Cleaning Devices During Dental Procedures. Mil Med 2023; 188:e80-e85. [PMID: 34114042 PMCID: PMC8344839 DOI: 10.1093/milmed/usab225] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 04/25/2021] [Accepted: 05/27/2021] [Indexed: 01/11/2023] Open
Abstract
INTRODUCTION The recent COVID-19 pandemic has underscored the necessity of protecting health care providers (HCPs) against the transmission of infectious agents during dental procedures. To this end, the effectiveness of several air cleaning devices (ACDs) in reducing HCPs exposure to aerosols generated during dental procedures was estimated, separately or in combination with each other. These ACDs were a chairside unit capturing aerosols at the source of generation, and four ambient ACDs: a portable ambient ACD; a negative pressure module; a custom made, fan-operated and wall-mounted air filter (WMAF); and a smaller and passive version of the latter. The last three ACDs were intended for mobile dental clinics (MDCs) only. MATERIALS AND METHODS This assessment was performed in two different environments: in a dental clinic operatory and in a MDC. Two dental personnel, acting in the roles of dentist and dental assistant, performed on simulated patient aerosol-generating and non-aerosol-generating procedures. For each 5-minute scenario, the cumulative exposure to airborne particulate matter 10 µm in size or smaller (PM10) was determined by calculating the sum of all 1 second readings obtained with personal and ambient air monitors. The effectiveness of the ACDs in capturing PM10 was estimated based on the capability of the ACDs to keep PM10 level at or below the initial background level. RESULTS In all conditions assessed in the dental clinic operatory, when both the chairside and portable ambient ACDs were functioning, an estimated effectiveness of 100% in capturing PM10 was achieved. In the MDC, in all conditions where the chairside ACD was used without the negative pressure module, an estimated effectiveness of 100% was also achieved. The simultaneous operation of the negative pressure module in the MDC, which led to a room negative pressure of -0.25 inch wc, reduced the chairside ACD's effectiveness in capturing aerosols. Conversely, the use of the WMAF in the MDC in combination with the chairside ACD further reduced exposure to PM10 below the initial background level. Nonetheless, in all conditions assessed in both settings (dental clinic operatory and MDC), larger visible aerosols were produced, often landing on the surrounding environment. A fair portion of these aerosols landed on the inside of the chairside ACD flange. CONCLUSIONS This assessment suggests that the use of the tested chairside ACD, by capturing aerosols at the source of generation, had the greatest impact on reducing exposure of dental personnel to PM10 produced during dental procedures. This study also indicates that such exposure is further reduced with the addition of an ambient ACD. However, creating a negative pressure room as high as -0.25 inch wc can lead to air turbulence reducing the effectiveness of ACDs in capturing aerosols at the source. Furthermore, the presence of uncaptured droplets and spatter on the surrounding environment supports the need to complement the use of engineering controls with proper administrative controls and personal protective equipment, as recommended by governmental agencies and the scientific community for preventing the transmission of infection in health care settings.
Collapse
Affiliation(s)
- T Maurais
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - J Kriese
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - M Fournier
- Directorate of Dental Services, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - L Langevin
- Directorate of Dental Services, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - B MacLeod
- Directorate of Dental Services, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - S Blier
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - J P Tessier-Guay
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - A Girardin
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| | - L Maheux
- Directorate of Force Health Protection, Canadian Forces Health Services Group Headquarters, Ottawa, ON K1A 0K2, Canada
| |
Collapse
|
4
|
Huart L, Fournier M, Dupuy R, Vacheresse R, Reinhardt M, Cubaynes D, Céolin D, Hervé du Penhoat MA, Renault JP, Guigner JM, Kumar A, Lutet-Toti B, Bozek J, Ismail I, Journel L, Lablanquie P, Penent F, Nicolas C, Palaudoux J. First (e,e) coincidence measurements on solvated sodium benzoate in water using a magnetic bottle time-of-flight spectrometer. Phys Chem Chem Phys 2023; 25:11085-11092. [PMID: 36484473 DOI: 10.1039/d2cp02982k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Sodium benzoate molecules solvated in water are studied using coincidence electron spectroscopy coupled with a liquid microjet device.
Collapse
Affiliation(s)
- L. Huart
- Synchrotron Soleil, 91192 Saint Aubin, France
- Université Paris-Saclay, CEA, CNRS, NIMBE, CEA Saclay, 91191 Gif-sur-Yvette, France
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université, UMR CNRS 7590, MHNH, 75252 Paris, France
| | - M. Fournier
- Synchrotron Soleil, 91192 Saint Aubin, France
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - R. Dupuy
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
- Fritz-Haber-Institut der Max-Planck-Gesellschaft, Faradayweg 4-6, 14195 Berlin, Germany
| | - R. Vacheresse
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - M. Reinhardt
- Nano and Molecular Systems Research Unit, University of Oulu, PO Box 3000, FI-90014, Finland
| | - D. Cubaynes
- ISMO, CNRS UMR 8214, Université Paris Sud, bâtiment 350, F-91405, Orsay, France
| | - D. Céolin
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - M. A. Hervé du Penhoat
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université, UMR CNRS 7590, MHNH, 75252 Paris, France
| | - J. P. Renault
- Université Paris-Saclay, CEA, CNRS, NIMBE, CEA Saclay, 91191 Gif-sur-Yvette, France
| | - J.-M. Guigner
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, Sorbonne Université, UMR CNRS 7590, MHNH, 75252 Paris, France
| | - A. Kumar
- Synchrotron Soleil, 91192 Saint Aubin, France
| | - B. Lutet-Toti
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - J. Bozek
- Synchrotron Soleil, 91192 Saint Aubin, France
| | - I. Ismail
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - L. Journel
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - P. Lablanquie
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - F. Penent
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| | - C. Nicolas
- Synchrotron Soleil, 91192 Saint Aubin, France
| | - J. Palaudoux
- Sorbonne Université, CNRS, Laboratoire de Chimie Physique – Matière et Rayonnement, LCP-MR, F-75005 Paris Cedex 05, France
| |
Collapse
|
5
|
Pénélope R, Campayo L, Fournier M, Le Gallet S, Gossard A, Grandjean A. Lead-vanadate sorbents for iodine trapping and their conversion into an iodoapatite-based conditioning matrix. Front Chem 2022; 10:1085868. [PMID: 36618862 PMCID: PMC9811818 DOI: 10.3389/fchem.2022.1085868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 12/12/2022] [Indexed: 12/24/2022] Open
Abstract
New lead-vanadate based sorbents were synthesized with the aim to entrap and confine gaseous iodine in off-gas streams coming from reprocessing facilities of spent nuclear fuel. Their synthesis relies on the shaping of a lead-vanadate, lead sulfide and alginic acid mix as millimetric beads. These beads were calcined between 220°C and 500°C to remove organic alginic compounds template. However, according to the calcination temperature, lead sulfide could be partially oxidized, limiting iodine loading capacity. A compromise temperature between 290°C and 350°C was found to remove most of the alginic acid template and avoiding lead sulfide oxidation. These sorbents were tested for iodine trapping in static conditions at 60°C. They performed well with a sorption capacity up to 155 mg.g-1 by forming PbI2. Furthermore, these iodine-loaded sorbents could be easily converted into an iodine-containing lead-vanadate apatite matrix by spark plasma sintering. A dense sample was produced for a sintering temperature of 500°C under 70 MPa. Such a material could be suitable for radioactive iodine conditioning in deep geological disposal. Finally, lead-vanadate sorbents could provide an easy way to entrap and confine radioactive iodine from off-gas streams into a durable material within a few steps.
Collapse
Affiliation(s)
- R. Pénélope
- CEA, DES, ISEC, DE2D, Université de Montpellier, Marcoule, France
| | - L. Campayo
- CEA, DES, ISEC, DE2D, Université de Montpellier, Marcoule, France,*Correspondence: L. Campayo,
| | - M. Fournier
- CEA, DES, ISEC, DE2D, Université de Montpellier, Marcoule, France
| | - S. Le Gallet
- ICB, UMR 6303 CNRS-Université Bourgogne Franche-Comté, Dijon, France
| | - A. Gossard
- CEA, DES, ISEC, DMRC, Université de Montpellier, Marcoule, France
| | - A. Grandjean
- CEA, DES, ISEC, DMRC, Université de Montpellier, Marcoule, France
| |
Collapse
|
6
|
Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Jouannaud C, Emile G, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, Martin AL, Everhard S, Di Meglio A. Factors associated with enrolment in clinical trials among women with early-stage breast cancer. ESMO Open 2022; 7:100513. [PMID: 35724624 PMCID: PMC9271499 DOI: 10.1016/j.esmoop.2022.100513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 05/16/2022] [Accepted: 05/17/2022] [Indexed: 11/26/2022] Open
Abstract
Background Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer. Methods We included 9516 patients with stage I-III breast cancer from the multicenter, prospective CANTO study (NCT01993498), followed-up until year 4 (Y4) post-diagnosis. We assessed factors associated with enrolment using multivariable logistic regression. In exploratory, propensity score matched analyses, we used multiple linear regression to evaluate the relationship of enrolment in clinical trials with the European Organisation for Research and Treatment of Cancer Quality Of Life (QoL) questionnaire (EORTC QLQ-C30) Summary Score and described clinical outcomes (distant disease event, invasive disease event, and death by any cause) according to enrolment. Results Overall, 1716 patients (18%) were enrolled in a clinical trial until Y4 post-diagnosis of breast cancer. Socioeconomic factors were not associated with enrolment. Centres of intermediate volume were most likely to enrol patients in clinical trials [versus low volume, odds ratio 1.45 (95% confidence interval (CI) 1.08-1.95), P = 0.0124]. Among 2118 propensity score matched patients, enrolment was associated with better QoL at Y4 (adjusted mean difference versus not enrolled 1.37, 95% CI 0.03-2.71, P = 0.0458), and clinical outcomes (enrolled versus not enrolled, distant disease event 7.3% versus 10.1%, P = 0.0206; invasive disease event 8.2% versus 10.5%, P = 0.0732; death by any cause 2.8% versus 3.7%, P = 0.2707). Conclusions In this large study, one in five patients enrolled on a clinical trial until Y4 after diagnosis of early breast cancer. Geographical and centre-related factors were significantly associated with enrolment in clinical trials. Inclusion in clinical trials seemed associated with improved QoL and clinical outcomes. Access to innovation for early-stage breast cancer patients should be encouraged and facilitated by overcoming organizational and geographical barriers to recruitment. The proportion of patients who access innovation through participation in clinical trials is generally limited. Rate of enrolment in clinical trials among women with early breast cancer exceeded what previously found in other settings. Clinical and geographical factors were associated to access to innovation in clinical trials. Enrolment in clinical trials is associated with better quality of life and clinical outcomes.
Collapse
Affiliation(s)
- D Presti
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - J Havas
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - D Soldato
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy
| | - P Lapidari
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
| | - E Martin
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France
| | - B Pistilli
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| | | | - G Emile
- Centre François Baclesse, Caen, France
| | - O Rigal
- Centre Henri Becquerel, Rouen, France
| | | | - P Soulie
- Institut de Cancérologie de L'ouest -Paul Papin, Angers, France
| | | | - C Tarpin
- Institut Paoli Calmettes, Marseille, France
| | - M Campone
- Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France
| | | | | | | | - A Di Meglio
- INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.
| |
Collapse
|
7
|
Labat G, Hayotte M, Brocq O, Bailly L, Fabre R, Fournier M, Breuil V, D’arripe Longueville F, Roux C. POS0953 IMPACT OF A WEARABLE ACTIVITY TRACKER ON DISEASE ACTIVITY IN SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOther studies have shown the ability of a wearable activity tracker (TAP) to improve physical activity (PA) in different rheumatic diseases. Given the importance of PA in spondyloarthritis, our hypothesis is that the use of a TAP could improve physical activity and thus disease activity.ObjectivesThe purpose of this study is to evaluate the impact of a TAP used to encourage PA on disease activity in patients with spondyloarthritis.MethodsIn this randomized controlled trial consisting of three 12-week stages (Figure 1). Patients with spondyloarthritis were randomized to a group with TAP (GT), or a group without TAP (GST). For the first stage, both groups received physical activity counseling. In the second 12-week stage, no patients received TAP. In the third 12-week stage, all patients received supervised PA combined with TAP for GT only. Disease activity, performance (assessed by the TM6 6-minute walk test), and quality of life (assessed by the Short Form 36 Health Survey Questionnaire [SF-36]) were assessed at 12, 24, and 36 weeks. The primary endpoint was the progression of relapses between baseline and 12 weeks.Figure 1.ResultsA total of 108 patients were included in the study. At 12 weeks, both groups showed a non-significant improvement in the number of relapses: mean change (Δ), -0.32 [95% CI-0.68;60.09] in GT and Δ, -0.38 [95% CI-0.68;60.09] in GST. But, differences in outcome between groups were not significant (p=0.87). The TM6 was improved in the GT and GST groups at 12, 24, and 36 weeks (p < 0.01, and p < 0.001, respectively). We observed improvement in different dimensions of the SF36, mainly in physical function, emotional role, general health, and physical pain at 12 weeks (p < 0.01).Multivariate analysis showed improvement over time in performance (p < 0.01) and moderate flare-ups (p < 0.01) without the influence of a PAR (p = 0.29, and p = 0.66, respectively).ConclusionTo our knowledge, our study is the first to explore the impact of TAP use on disease activity in spondyloarthritis.We observed an improvement in disease activity, physical performance and quality of life without significant difference between the two groups. The lack of difference could be explained by the encouragement of physical activity to both groups. But also by the fact that our patients presented a significant number of severe relapses. Indeed, authors have shown the limits of the use of TAP in severe diseases, particularly in pulmonary pathologies [1].Our study did not show any effect of the use of a connected object on disease activity. However, this study confirmed the benefits of physical activity on disease activity, quality of life and physical performance in patients with spondyloarthritis.References[1]Bentley CL, Powell L, Potter S, et al. The use of a smartphone app and an activity tracker to promote physical activity in the management of chronic obstructive pulmonary disease: randomized controlled feasibility study. J.M.I.R. MHealth UHealth 2020;8:e16203. https://doi.org/10.2196/16203.Disclosure of InterestsGuillaume Labat: None declared, Meggy Hayotte: None declared, Olilvier Brocq: None declared, laurent bailly: None declared, Roxane fabre: None declared, manuella Fournier: None declared, Véronique Breuil: None declared, fabienne d’arripe longueville: None declared, Christian Roux Speakers bureau: Pfizer, BMS, Novartis, Lilly, Grant/research support from: Novartis and Lilly
Collapse
|
8
|
Saxena A, Shou L, Fournier M. Results of Lisfranc’s Surgery in Athletic Patients. Muscles Ligaments Tendons J 2021. [DOI: 10.32098/mltj.04.2021.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Saxena
- Department of Sports Medicine, Sutter-Palo Alto, El Camino Real, Palo Alto (CA), U.S.A
| | - L. Shou
- Reconstructive Orthopedics, Medford (NJ), U.S.A
| | - M. Fournier
- Gundersen Health System, LaCrosse (WI), U.S.A
| |
Collapse
|
9
|
Mottet T, Soubeyran P, Godbert Y, Cabart M, Roubaud G, Chakiba C, Bourcier K, Haik L, Lebreton C, Floquet A, Charitansky H, Fournier M, Toulmonde M, Pernot S, Annonay M, Enfedaque S, Cassauba S, Italiano A, Mathoulin-Pelissier S, Tueux NQ. 1613P What are the barriers to routine clinical use of teleconsultation in oncology? A retrospective study on patient’s and their physician’s satisfaction with 603 video teleconsultations. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Martin AL, Everhard S, Jouannaud C, Levy C, Rigal O, Fournier M, Soulié P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, André F, Vaz-Luis I, Di Meglio A. 134P Enrolment in clinical trials (CT) among patients (pts) with early breast cancer (BC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Houvenaeghel G, Cohen M, Dammacco MA, D'Halluin F, Regis C, Gutowski M, Acker O, Fournier M, Bannier M, Lusque A, Jouve E. Prophylactic nipple-sparing mastectomy with immediate breast reconstruction: results of a French prospective trial. Br J Surg 2021; 108:296-301. [PMID: 33793719 DOI: 10.1093/bjs/znaa082] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 10/14/2020] [Indexed: 12/25/2022]
Abstract
BACKGROUND Nipple-sparing mastectomy (NSM) with immediate breast reconstruction (IBR) is used increasingly when performing a prophylactic mastectomy. Few prospective studies have reported on complication rates. This complementary trial to the French prospective multicentre MAPAM trial aimed to evaluate the nipple-areola complex (NAC) necrosis rate in prophylactic NSM with IBR. METHODS Patient characteristics and surgical data were recorded. Morbidity after prophylactic NSM with a focus on NAC necrosis was analysed. RESULTS Among 59 women undergoing prophylactic NSM, 19 (32 per cent) of the incisions were partly on the NAC. Reconstructions were performed with 46 definitive implants and 13 expanders. The crude rate of postoperative complications was 25 per cent (15 patients). Complete NAC necrosis was reported in two women (3 per cent) and partial or total necrosis in nine (15 per cent). No NAC resection was necessary. Median BMI was lower in women with total or partial NAC necrosis compared with the others (20.0 versus 21.3 kg/m2 respectively; P = 0.034). CONCLUSION Results of this prospective study confirm that prophylactic NSM with IBR is associated with a low risk of total NAC necrosis.
Collapse
Affiliation(s)
- G Houvenaeghel
- Department of Surgical Oncology, Paoli Calmettes Institute and Centre de Recherche en Cancerérologie de Marseille (CRCM), Aix-Marseille University, Marseille, France
| | - M Cohen
- Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France
| | - M A Dammacco
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - F D'Halluin
- Surgery Department, L'Etablissement Rennais du Sein, Centre Hospitalier Privé St Grégoire, St Grégoire, France
| | - C Regis
- Department of Surgical Oncology, Centre Oscar Lambret, Lille, France
| | - M Gutowski
- Department of Surgical Oncology, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France
| | - O Acker
- Surgery Department, Pôle Santé Léonard de Vinci, Chambray les Tours, France
| | - M Fournier
- Department of Surgical Oncology, Institut Bergonie, Bordeaux, France
| | - M Bannier
- Department of Surgical Oncology, Paoli Calmettes Institute, Marseille, France
| | - A Lusque
- Department of Biostatistics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
| | - E Jouve
- Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
| | | |
Collapse
|
12
|
Bultelle F, Boutet I, Devin S, Caza F, St-Pierre Y, Péden R, Brousseau P, Chan P, Vaudry D, Le Foll F, Fournier M, Auffret M, Rocher B. Molecular response of a sub-antarctic population of the blue mussel (Mytilus edulis platensis) to a moderate thermal stress. Mar Environ Res 2021; 169:105393. [PMID: 34217095 DOI: 10.1016/j.marenvres.2021.105393] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 06/08/2021] [Accepted: 06/14/2021] [Indexed: 06/13/2023]
Abstract
The Kerguelen Islands (49°26'S, 69°50'E) represent a unique environment due to their geographical isolation, which protects them from anthropogenic pollution. The ability of the endemic mussel, part of the Mytilus complex, to cope with moderate heat stress was explored using omic tools. Transcripts involved in six major metabolic functions were selected and the qRT-PCR data indicated mainly changes in aerobic and anaerobic energy metabolism and stress response. Proteomic comparisons revealed a typical stress response pattern with cytoskeleton modifications and elements suggesting increased energy metabolism. Results also suggest conservation of protein homeostasis by the long-lasting presence of HSP while a general decrease in transcription is observed. The overall findings are consistent with an adaptive response to moderate stresses in mussels in good physiological condition, i.e. living in a low-impact site, and with the literature concerning this model species. Therefore, local blue mussels could be advantageously integrated into biomonitoring strategies, especially in the context of Global Change.
Collapse
Affiliation(s)
- F Bultelle
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| | - I Boutet
- Station Biologique de Roscoff CNRS, Laboratory Adaptation & Diversity in Marine Environment (UMR7144 CNRS-SU), Sorbonne Université, Roscoff, France.
| | - S Devin
- UMR 7360 LIEC, Université Metz-Lorraine, France.
| | - F Caza
- INRS-Institut Armand-Frappier, 531 Boul. des Prairies, Laval, Québec, H7V 1B7, Canada.
| | - Y St-Pierre
- INRS-Institut Armand-Frappier, 531 Boul. des Prairies, Laval, Québec, H7V 1B7, Canada.
| | - R Péden
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France; UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, Université de REIMS Champagne-Ardenne, Campus Moulin de la Housse, 51687, Reims, France.
| | - P Brousseau
- Institut des Sciences de la mer, Le Parc de la rivière Mitis, Sainte-Flavie, Québec, G0J 2L0, Canada.
| | - P Chan
- Normandie Univ, UNIROUEN, Plateforme PISSARO, IRIB, 76821, Mont-Saint-Aignan, France.
| | - D Vaudry
- Normandie Univ, UNIROUEN, Plateforme PISSARO, IRIB, 76821, Mont-Saint-Aignan, France; Normandie Univ, UNIROUEN, INSERM U1239 DC2N, 76821, Mont-Saint-Aignan, France.
| | - F Le Foll
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| | - M Fournier
- Institut des Sciences de la mer, Le Parc de la rivière Mitis, Sainte-Flavie, Québec, G0J 2L0, Canada.
| | - M Auffret
- UMR CNRS 6539-LEMAR/ Laboratoire des Sciences de l'Environnement Marin, Technopôle Brest-Iroise, 29280, Plouzané, France.
| | - B Rocher
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| |
Collapse
|
13
|
Gillaizeau F, Cambier S, Fournier M, Leuillet S. Prise en compte des événements récurrents dans le cadre des essais cliniques. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.04.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
14
|
Bertaut A, Blanc J, Pistilli B, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu P, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Martin AL, Jacquet Jacquet A, Briot N, Vaz-Luis I. 151P Impact of germline BRCA (gBRCA) mutation (m) status on clinical characteristics and patterns of care among women with early breast cancer (eBC): An analysis of the observational prospective CANTO cohort. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
15
|
Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol 2021; 204:96-106. [PMID: 33346915 DOI: 10.1111/cei.13567] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 11/22/2020] [Accepted: 12/02/2020] [Indexed: 12/24/2022] Open
Abstract
A clearer understanding of the tumor immune microenvironment (TIME) in metastatic clear cell renal cell carcinoma (ccRCC) may help to inform precision treatment strategies. We sought to identify clinically meaningful TIME signatures in ccRCC. We studied tumors from 39 patients with metastatic ccRCC using quantitative multiplexed immunofluorescence and relevant immune marker panels. Cell densities were analyzed in three regions of interest (ROIs): tumor core, tumor-stroma interface and stroma. Patients were stratified into low- and high-marker density groups using median values as thresholds. Log-rank and Cox regression analyses while controlling for clinical variables were used to compare survival outcomes to patterns of immune cell distributions. There were significant associations with increased macrophage (CD68+ CD163+ CD206+ ) density and poor outcomes across multiple ROIs in primary and metastatic tumors. In primary tumors, T-bet+ T helper type 1 (Th1) cell density was highest at the tumor-stromal interface (P = 0·0021), and increased co-expression of CD3 and T-bet was associated with improved overall survival (P = 0·015) and survival after immunotherapy (P = 0·014). In metastatic tumor samples, decreased forkhead box protein 3 (FoxP3)+ T regulatory cell density correlated with improved survival after immunotherapy (P = 0·016). Increased macrophage markers and decreased Th1 T cell markers within the TIME correlated with poor overall survival and treatment outcomes. Immune markers such as FoxP3 showed consistent levels across the TIME, whereas others, such as T-bet, demonstrated significant variance across the distinct ROIs. These findings suggest that TIME profiling outside the tumor core may identify clinically relevant associations for patients with metastatic ccRCC.
Collapse
Affiliation(s)
- A Hajiran
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - N Chakiryan
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - A M Aydin
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - L Zemp
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J Nguyen
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - J M Laborde
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J Chahoud
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - P E Spiess
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - S Zaman
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - S Falasiri
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - M Fournier
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J K Teer
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J Dhillon
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - S McCarthy
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - C Moran-Segura
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - E N Katende
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - W J Sexton
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J M Koomen
- Department of Proteomics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J Mulé
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Y Kim
- Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - B Manley
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.,Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
16
|
Fournier M, Dossier A, Mageau A, Berleur M, Delaval L, Goulenok T, Rouzaud D, Papo T, Sacré K. Thromboses artérielles et infection COVID-19. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
|
18
|
Touré M, Poder TG, Safianyk C, Fournier M, Ganache I, Pomey MP, Gagnon MP. Patients, users, caregivers and citizens’ involvement in local HTA unit in Quebec: a survey. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Increasing emphasis is given on involving patients in health technology assessment (HTA). While this is mainly done at the level of regional and national HTA agencies, this tendency is also emerging in local HTA units. In this study we provide the results of a survey conducted in local HTA units in the province of Quebec, Canada. The aim of the survey was to provide a panorama of local HTA units practices to involve patients in their process, their interest in doing so, and their information needs for this. The survey was conducted in 2017 with a response rate of 11 units over a possibility of 12. Results indicate that only 3 units over 11 never involved patients or members of the public in their process and that all will involve them in the next few years. The three most important needs identified in the HTA units were: recruiting and selecting patients; integrating experiential knowledge; and knowing and implementing the winning conditions for partnership. To conclude, patient involvement in local HTA units is quickly evolving; that is why the latter urgently need tools to involve more effectively patients and members of the public in their process.
Key messages
There is a need to develop tools to involve patients in HTA process. Patient involvement in local HTA units is quickly evolving.
Collapse
Affiliation(s)
- M Touré
- University of Sherbrooke, Sherbrooke, Canada
| | | | | | | | | | | | | |
Collapse
|
19
|
Lapidari P, Gbenou A, Havas J, Martin E, Pistilli B, Martin AL, Everhard S, Coutant C, Cottu P, Lesur A, Lerebours F, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, André F, Vaz-Luis I, Di Meglio A. 1817MO Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received granulocyte-colony stimulating factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
20
|
Gillaizeau F, Le Gal C, Maudet C, Fournier M, Leuillet S. Méthodes de gestion des valeurs sous des seuils de détection ou de quantification. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.03.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
21
|
Coutard JG, Brun M, Fournier M, Lartigue O, Fedeli F, Maisons G, Fedeli JM, Nicoletti S, Carras M, Duraffourg L. Volume Fabrication of Quantum Cascade Lasers on 200 mm-CMOS pilot line. Sci Rep 2020; 10:6185. [PMID: 32277096 PMCID: PMC7148313 DOI: 10.1038/s41598-020-63106-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 03/17/2020] [Indexed: 11/17/2022] Open
Abstract
The manufacturing cost of quantum cascade lasers is still a major bottleneck for the adoption of this technology for chemical sensing. The integration of Mid-Infrared sources on Si substrate based on CMOS technology paves the way for high-volume low-cost fabrication. Furthermore, the use of Si-based fabrication platform opens the way to the co-integration of QCL Mid-InfraRed sources with SiGe-based waveguides, enabling realization of optical sensors fully integrated on planar substrate. We report here the fabrication and the characterization of DFB-QCL sources using top metal grating approach working at 7.4 µm fully implemented on our 200 mm CMOS pilot line. These QCL featured threshold current density of 2.5 kA/cm² and a linewidth of 0.16 cm−1 with a high fabrication yield. This approach paves the way toward a Mid-InfraRed spectrometer at the silicon chip level.
Collapse
Affiliation(s)
- J G Coutard
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - M Brun
- mirSense - Centre d'intégration NanoINNOV, Bâtiment 863, 8 avenue de la Vauve, F91120, Palaiseau, France
| | - M Fournier
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - O Lartigue
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - F Fedeli
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - G Maisons
- mirSense - Centre d'intégration NanoINNOV, Bâtiment 863, 8 avenue de la Vauve, F91120, Palaiseau, France
| | - J M Fedeli
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - S Nicoletti
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France
| | - M Carras
- mirSense - Centre d'intégration NanoINNOV, Bâtiment 863, 8 avenue de la Vauve, F91120, Palaiseau, France
| | - L Duraffourg
- Univ. Grenoble Alpes, CEA, LETI, F38054, Grenoble, France.
| |
Collapse
|
22
|
Chatelain S, Mimoun M, Chaouat M, Fournier M, Boccara D. [Quick screening for Body Dysmorphic Disorder in a plastic surgery population in France]. Encephale 2020; 46:190-192. [PMID: 32151455 DOI: 10.1016/j.encep.2019.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 10/18/2019] [Accepted: 10/20/2019] [Indexed: 10/24/2022]
Abstract
INTRODUCTION All plastic surgeons are frequently faced with patients with Body Dysmorphic Disorder (BDD). However, no screening test exists in French to help the plastic surgeons to diagnose this disease. The Body Dysmorphic Disorder Questionnaire (BDDQ) is the Gold Standard to easily detect BDD in consultation with any non-psychiatric physician. The aim of this study was to translate and validate the BDDQ into French to help plastic surgeons to detect BDD before the surgery. This way, plastic surgeons will be able to provide an optimal medical care and to reduce the risk of psychiatric collapse. METHODS We asked Katherine Philipps for her approval to use her BDDQ for our study, and thereafter we translated it respecting the criteria of the World Health Organization. We first evaluated the psychometric qualities of the BDDQ in French and then its reproducibility and its sensitivity to change. RESULTS A French version of the BDDQ appeared to be reliable and comprehensible. The questionnaire has been tested on a sample of patients in plastic surgery consultation, at a T moment and a T plus one month to certify its reproducibility and its sensitivity to change. CONCLUSION These results permit to claim that the French version of the BDDQ is now validated to detect patients with a BDD in a plastic surgery consultation.
Collapse
Affiliation(s)
- S Chatelain
- Service de chirurgie plastique, reconstructrice et esthétique, centre de traitement des brulés, hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France.
| | - M Mimoun
- Service de chirurgie plastique, reconstructrice et esthétique, centre de traitement des brulés, hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Chaouat
- Service de chirurgie plastique, reconstructrice et esthétique, centre de traitement des brulés, hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - M Fournier
- Service de chirurgie plastique, reconstructrice et esthétique, centre de traitement des brulés, hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
| | - D Boccara
- Service de chirurgie plastique, reconstructrice et esthétique, centre de traitement des brulés, hôpital Saint Louis, 1, avenue Claude Vellefaux, 75010 Paris, France
| |
Collapse
|
23
|
Licaj I, Dabakuyo S, Dauchy S, Vaz Luis I, Charles C, Lemogne C, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Petit T, Dalenc F, Rouanet P, Arnaud A, Lemonnier J, Everhard S, Cottu P, Joly F. Baseline quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): The French multicentric prospective CANTO cohort study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Lebrun C, Vukusic S, Abadie V, Achour C, Ader F, Alchaar H, Alkhedr A, Andreux F, Androdias G, Arjmand R, Audoin B, Audry D, Aufauvre D, Autreaux C, Ayrignac X, Bailbe M, Benazet M, Bensa C, Bensmail D, Berger E, Bernady P, Bertagna Y, Biotti D, Blanchard-Dauphin A, Bonenfant J, Bonnan M, Bonnemain B, Borgel F, Botelho-Nevers E, Boucly S, Bourre B, Boutière C, Branger P, Brassat D, Bresch S, Breuil V, Brochet B, Brugeilles H, Bugnon P, Cabre P, Camdessanché JP, Carra-Dalière C, Casez O, Chamouard JM, Chassande B, Chataignier P, Chbicheb M, Chenet A, Ciron J, Clavelou P, Cohen M, Colamarino R, Collongues N, Coman I, Corail PR, Courtois S, Coustans M, Creange A, Creisson E, Daluzeau N, Davenas C, De Seze J, Debouverie M, Depaz R, Derache N, Divio L, Douay X, Dulau C, Durand-Dubief F, Edan G, Elias Z, Fagniez O, Faucher M, Faucheux JM, Fournier M, Gagneux-Brunon A, Gaida P, Galli P, Gallien P, Gaudelus J, Gault D, Gayou A, Genevray M, Gentil A, Gere J, Gignoux L, Giroux M, Givron P, Gout O, Grimaud J, Guennoc AM, Hadhoum N, Hautecoeur P, Heinzlef O, Jaeger M, Jeannin S, Kremer L, Kwiatkowski A, Labauge P, Labeyrie C, Lachaud S, Laffont I, Lanctin-Garcia C, Lannoy J, Lanotte L, Laplaud D, Latombe D, Lauxerois M, Le Page E, Lebrun-Frenay C, Lejeune P, Lejoyeux P, Lemonnier B, Leray E, Loche CM, Louapre C, Lubetzki C, Maarouf A, Mada B, Magy L, Maillart E, Manchon E, Marignier R, Marque P, Mathey G, Maurousset A, Mekies C, Merienne M, Michel L, Milor AM, Moisset X, Montcuquet A, Moreau T, Morel N, Moussa M, Naudillon JP, Normand M, Olive P, Ouallet JC, Outteryck O, Pacault C, Papeix C, Patry I, Peaureaux D, Pelletier J, Pichon B, Pittion S, Planque E, Pouget MC, Pourcher V, Radot C, Robert I, Rocher F, Ruet A, Ruet A, Saint-Val C, Salle JY, Salmon A, Sartori E, Schaeffer S, Stankhof B, Taithe F, Thouvenot E, Tizon C, Tourbah A, Tourniaire P, Vaillant M, Vermersch P, Vidil S, Wahab A, Warter MH, Wiertlewski S, Wiplosz B, Wittwer B, Zaenker C, Zephir H. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2019; 175:341-357. [DOI: 10.1016/j.neurol.2019.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Revised: 03/31/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
|
25
|
Doudoux H, Fournier M, Vercueil L. Postictal syndrome: The forgotten continent. An overview of the clinical, biochemical and imaging features. Rev Neurol (Paris) 2019; 176:62-74. [PMID: 31160075 DOI: 10.1016/j.neurol.2019.02.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 01/30/2019] [Accepted: 02/19/2019] [Indexed: 01/09/2023]
Abstract
Postictal syndrome (PIS) encompasses the clinical, biological, electroencephalographic (EEG) and magnetic resonance imaging (MRI) signs that follow the termination of a seizure. These signs occur as soon as the epileptic discharge ends, but might remain for a substantially long period of time, making them amenable to clinical observation. As a direct consequence, neurologists and intensivists are more frequently attending patients with PIS than during their seizure. Moreover, careful PIS documentation may help physicians to diagnose epileptic seizure from other non-epileptic disorders. Careful analysis of PIS could also be helpful to better characterize the seizure (seizure subtypes, and to some extent, the localization and/or lateralization of the seizure). This article aims to review the main clinical, biological, EEG and MRI components of PIS, discuss differential diagnoses and propose a general clinical attitude, based on the acronym "WAITTT": W for "Watch", to monitor and investigate PIS in order to provide relevant information on seizure, AIT for "Avoid Inappropriate Treatment", to underscore the risk carrying out unnecessary drug injections and intensive care procedures in the setting of a self-limited symptomatology, and TT for "Take Time", to keep in mind that time remains the clinician's best ally for treating patients with PIS.
Collapse
Affiliation(s)
- H Doudoux
- EFSN, centre de compétence Grenoble epilepsies rares, university Grenoble Alpes, Inserm, U1216, CHU de Grenoble Alpes, Grenoble institut neurosciences, 38000 Grenoble, France
| | - M Fournier
- EFSN, centre de compétence Grenoble epilepsies rares, university Grenoble Alpes, Inserm, U1216, CHU de Grenoble Alpes, Grenoble institut neurosciences, 38000 Grenoble, France
| | - L Vercueil
- EFSN, centre de compétence Grenoble epilepsies rares, university Grenoble Alpes, Inserm, U1216, CHU de Grenoble Alpes, Grenoble institut neurosciences, 38000 Grenoble, France.
| |
Collapse
|
26
|
Tunon de Lara C, Leroux J, Bonnet F, Debled M, Barrouk-Simonet E, Quenel-Tueux N, Lagarde P, Chassaigne F, Esnaud T, Fournier M, Bubien V, Breton-Callu C, Charitansky H, Petit A, Mathoulin-Pelissier S, Macgrogan G, Longy M, Sevenet N. Abstract P5-09-07: Risk reducing strategy in germline BRCA mutated patients with locally advanced breast cancer. Establishing mastectomy as a preventing procedure of local recurrence. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-09-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Neoadjuvant chemotherapy (NAC) is proposed for locally advanced breast cancer (LABC) to increase the breast conservative treatment (BCT). In France, mastectomy is the risk-reducing prophylactic surgical strategy only for pre-symptomatic germline BRCA-mutated (gBRCAm) patients. On the other hand, BCT is proposed to all patients following NAC based on clinical response, regardless the gBRCAm status. The aim of this retrospective study is to evaluate the risk of local recurrence (LR) according to BRCA status.
Patients and methods
Inclusion criteria were: (i) patients treated for unilateral LABC, T2-3, N≥0, M0 by NAC, and (ii) patients who underwent germline BRCA screening. , using targeted next-generation screening, was carried out either during NAC (rapid process) or after surgery. Deleterious mutations were confirmed using Sanger sequencing before passing on the results to the clinical geneticist. Some gBRCAm patients from Olympia study were also included. Patients were followed-up over a long term for overall survival, LR and disease-free survival. Chi-square and Fischer test were used to generate statistical comparison.
Results
Between 2007 and 2015, 988 women were treated for LABC at our institution. Among them, 151 patients underwent clinical genetic testing for gBRCAm based on these criteria: young age at diagnosis or familial history of breast or ovarian cancer or histological characteristics as grade 2/3, Her2-3+ or basal like. A total of 122 patients were included in the study; 28 patients had gBRCAm status and no mutations were detected in 94 patients (wtBRCA). Significant differences between the two groups (gBRCAm vs wtBRCA) were observed for
Mean age, (36.7 vs 40.1y (p=0.0032) ,
Intrinsic tumor subtypes basal like (64.3% vs 42.5%, p=0.0432)
ER are more often negative (21.4% vs 46.8%, p=0.0165).
Among the 30 patients who underwent BRCA screening during NAC and eligible for BCT, 8 of the 9 patients with gBRCAm choose mastectomy (88%). Among the 92 patients with screening mutation after breast cancer treatment, 5 of the 19 patients with gBRCAm had a mastectomy (28%). In the 28 gBRCAm patients, 15 had a BCT and 13 a mastectomy. In the 94 wtBRCA patients, 67 had a BCT and 27 a mastectomy. After a follow-up of 4.32 years, we observed 8 relapses, 5 LRs after BCT and 3 contro-lateral relapses. Of the 5 LRs, 3 came from 15 gBRCAm with BCT and 2 of the 67 wtBRCA (p=0.0403).
Discussion
In this selected subgroup of patients, gBRCAm rate is higher (23%) than the rate based on familial criteria for BRCA testing (12%). Regarding the rationale for BCT or mastectomy procedure in LABC and pre-symptomatic gBRCAm patients, this study led us to establish mastectomy as risk-reducing strategy in a sole surgery procedure for gBRCAm patients. Moreover, 88% gBRCAm patients chose mastectomy; the mastectomy rate was lower when the patient was unaware of their BRCA status (26%). The LR rate was higher in the gBRCAm vs wtBRCA with a statistical difference. In LABC patients with high genetic risk, the knowledge of mutation status could influence patients' and surgeons' choice of surgery. In case of gBRCAm status, mastectomy is recommended to decrease LR risk.
Citation Format: Tunon de Lara C, Leroux J, Bonnet F, Debled M, Barrouk-Simonet E, Quenel-Tueux N, Lagarde P, Chassaigne F, Esnaud T, Fournier M, Bubien V, Breton-Callu C, Charitansky H, Petit A, Mathoulin-Pelissier S, Macgrogan G, Longy M, Sevenet N. Risk reducing strategy in germline BRCA mutated patients with locally advanced breast cancer. Establishing mastectomy as a preventing procedure of local recurrence [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-09-07.
Collapse
Affiliation(s)
- C Tunon de Lara
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - J Leroux
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - F Bonnet
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - M Debled
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - E Barrouk-Simonet
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - N Quenel-Tueux
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - P Lagarde
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - F Chassaigne
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - T Esnaud
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - M Fournier
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - V Bubien
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - C Breton-Callu
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - H Charitansky
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - A Petit
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | | | - G Macgrogan
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - M Longy
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| | - N Sevenet
- Institut Bergonié, Bordeaux, France; Université de Bordeaux, Bordeaux, France
| |
Collapse
|
27
|
Affiliation(s)
- A. Saxena
- Department of Sports Medicine, Palo Alto Medical Foundation, Palo Alto, CA
| | - M.ST. Louis
- Department of Sports Medicine, Palo Alto Medical Foundation, Palo Alto, CA
| | - M. Fournier
- Department of Sports Medicine, Palo Alto Medical Foundation, Palo Alto, CA
| |
Collapse
|
28
|
Rogers R, Fournier M, Sanchez L, Aminzadeh M, Marban E. DMD TREATMENT: ANIMAL MODELS. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Johnson J, Kanagavelu S, Rachid H, Sakoda C, Li L, Vaturi S, Fournier M, Smith R, Marban L, Al-Daccak R, Rodriguez-Borlado L. Multiple administration of allo-CDCs showed additional improvement when compared with single treatment in a Duchenne muscular dystrophy model. Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30332-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Nikul’shina MS, Mozhaev AV, Minaev PP, Fournier M, Lancelot C, Blanchard P, Payen E, Lamonier C, Nikul’shin PA. Application of Heteropolyacid H4SiMo3W9O40 for the Preparation of Bimetallic MoWS2/Al2O3 Hydrotreatment Catalysts. Kinet Catal 2018. [DOI: 10.1134/s0023158417060088] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
31
|
Cottu PH, Amar Y, Pistilli B, Bonsang-Kitzis H, Lesur A, Lerebours F, Vanlemmens L, Tredan O, Levy C, Jouannaud C, Fournier M, Soulie P, Rigal O, Giacchetti S, Arnaud A, Arsene O, Savignoni A, Mesleard C, Andre F, Arveux P. Abstract P6-12-18: CANTOCHEM: Analysis of chemotherapy practice and early side effects in the 6090 first patients from the prospective CANTO cohort. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
There is no large prospective trial assessing mid-term adverse effects of adjuvant chemotherapy. In order to address this question, we developed CANTO (CANcer TOxicities - NCT01993498 - http://etudecanto.org/), a prospective trial dedicated to the quantification of side effects after treatment for patients with early breast cancer and to develop predictors of such toxicities. The aim of this presentation is to assess chemotherapy (CT) practice and to report toxicities that persist 3-6 months after CT.
Methods
CANTO is a prospective study enrolling newly diagnosed invasive cT0-cT3, cN0-3, M0 breast cancer patients (pts) of 26 French comprehensive cancer centers. The study has included 10 500 patients at the time of submission. Pts are assessed at diagnosis, 3-6, 12, 36, 48 and 60 months after treatment completion. CANTO collects >100 items related to toxicities. In the current study, we focus on the first set of data available from the trial (1st database lock, n=6090). We here assess CT practice and toxicities at 3 months.
Results
Information about (neo)adjuvant CT (NACT/ACT) is available in 5805 pts (96%). Median age at diagnosis was 57y (22-93). Pts had HR+/HER2-, HER2+ or triple negative (TN) tumors in 74%, 15% and 11% of cases. Ki67 was assessed in 70%, and genomic tests in 1% of pts, respectively.
Overall, 3074 pts (53%) received CT, either adjuvant (ACT: 76%) or neoadjuvant (NACT: 24%). ACT/NACT pts (84%) received a sequential anthracyclines–taxanes based 6 courses CT schedule. CT was administered in 44.7%, 87.2% and 92.3% of HR+/HER2+/TN tumors, respectively. ACT was administered in 73.2% of pT2+ pts (vs 36.0% in pT0-1 – p<.001)) and in 74.7% in pN1+pts (vs 36.7% in pN0 – p<.001)). After NACT, pts had yPT0 (32.3%) and/or ypN0 (64.6%) for an overall 28.9% pCR rate.
We focus here on clinically most relevant patient reported symptoms at 3 m (any grade).
side effects at 3m no CT (%)CT (%)p valuePain76.682.1<.001Neurological symptom4768.7<.001GI symptom34.342.1<.001CV sympton8.110.20.011
Pain complaint was recorded in 3596 pts (97.2% of pts with available data), with a median value of 4 on the VAS (range 1-10). In ACT/NACT pts, muscle and joint pain were predominant. Neurological symptoms were seen in 3024 pts (59%), the most frequent pertaining to cognitive disorder (attention trouble, CT: 61.2% vs noCT: 56% - p=.06) and peripheral neuropathy (overall 31%). Paresthesias and sensory neuropathy were much more frequent in CT vs noCT pts: respectively 37.3% vs 20.3% and 25.7% vs 12.8% (both p<.001). Of note, pts receiving paclitaxel had more peripheral neuropathy (92.3% vs 69% in docetaxel pts – p=.07). Diarrhea was the most frequent GI symptom post CT: 44.5% vs 33.2%, p< 0.001. CV symptoms (NOS) were slightly more frequent after CT.
Conclusions
In this real life, prospective cohort, CT is frequently prescribed and appears in good compliance with current guidelines. Overall, symptoms burden at treatment completion is strikingly high, and much higher in pts receiving CT. A special attention should be given to pain and neurological symptoms. Dedicated questionnaires and sub-studies will explore in depth these side effects. Extended analyses of CT practice and toxicities will be presented.
Citation Format: Cottu PH, Amar Y, Pistilli B, Bonsang-Kitzis H, Lesur A, Lerebours F, Vanlemmens L, Tredan O, Levy C, Jouannaud C, Fournier M, Soulie P, Rigal O, Giacchetti S, Arnaud A, Arsene O, Savignoni A, Mesleard C, Andre F, Arveux P. CANTOCHEM: Analysis of chemotherapy practice and early side effects in the 6090 first patients from the prospective CANTO cohort [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-18.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - Y Amar
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - B Pistilli
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - H Bonsang-Kitzis
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Lesur
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - F Lerebours
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - L Vanlemmens
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Tredan
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Levy
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Jouannaud
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - M Fournier
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - P Soulie
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Rigal
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - S Giacchetti
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Arnaud
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Arsene
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Savignoni
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Mesleard
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - F Andre
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - P Arveux
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| |
Collapse
|
32
|
Fournier M, Huchon C, Ngo C, Bensaid C, Bats AS, Combe P, le FrèreBelda MA, Fournier L, Berger A, Lecuru F. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis. Eur J Surg Oncol 2018; 44:750-753. [PMID: 29580734 DOI: 10.1016/j.ejso.2018.01.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Revised: 11/23/2017] [Accepted: 01/03/2018] [Indexed: 11/24/2022] Open
Abstract
AIM Rectosigmoid resection is often performed during cytoreductive surgery for ovarian cancer, to achieve the goal of no residual tumour. Here, we evaluated the morbidity associated with rectosigmoid resection and the underlying risk factors. METHODS We retrospectively assessed consecutive patients managed with rectosigmoid resection during cytoreductive surgery for ovarian cancer at our centre in Paris, France, between 2005 and 2013. All previously identified risk factors were analysed. Major complications were defined as grade III-IV in the Clavien-Dindo classification. RESULTS Of 228 patients, 116 had primary and 112 interval surgery; 43/228 [18.9%]; experienced major complications, and these were more common after primary surgery [24.1% vs. 13.4%, p = .04]. The 69 patients who had rectosigmoid resection [33 primary vs. 36 interval surgery, p = .32] had a higher morbidity rate compared to the other patients [30.4% vs. 14.6%, p = .006]. The anastomotic leakage rate was 2.89%. By multivariate logistic regression, independent risk factors for morbidity were postmenopausal status [adjusted odds ratio (aOR), 13.7; 95% confidence interval (95%CI), 1.2;161.9], surgery after neoadjuvant chemotherapy [aOR, 4.4; 95%CI, 1.1;18.8], and peritoneal stripping of the left; paracolic gutter [aOR, 11.3; 95%CI, 2.3;54.3]. CONCLUSION The morbidity of rectosigmoid resection during cytoreductive surgery for ovarian cancer seems acceptable. Ileostomy does not seem associated with a lower risk of major complications or adjuvant bevacizumab with a higher complication rate.
Collapse
Affiliation(s)
- M Fournier
- Gynecologic Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France.
| | - C Huchon
- Obstetrics and Gynecology Department, CHI Poissy-St-Germain, Université Versailles- Saint-Quentin en Yvelines, Poissy, France; EA 7285, Risques Cliniques et Sécurité en Santé des Femmes, Université Versailles-Saint- Quentin en Yvelines, Versailles, France
| | - C Ngo
- Gynecologic Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France; Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; UMR S 1124, Faculté de Médecine, Université Paris Descartes, Paris, France
| | - C Bensaid
- Gynecologic Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - A S Bats
- Gynecologic Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France; Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ARCAGY-GINECO, Hôpital Hôtel Dieu, 1 parvis Notre Dame, 75004, Paris, France; UMR S 1124, Faculté de Médecine, Université Paris Descartes, Paris, France
| | - P Combe
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ARCAGY-GINECO, Hôpital Hôtel Dieu, 1 parvis Notre Dame, 75004, Paris, France; Medical Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - M A le FrèreBelda
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Pathology Department, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - L Fournier
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Imaging Department, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - A Berger
- Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; General and Digestive Surgery, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - F Lecuru
- Gynecologic Oncology, Centre Expert Oncologie Gynécologique, Paris Descartes- Hôpital Européen Georges Pompidou, APHP, Paris, France; Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ARCAGY-GINECO, Hôpital Hôtel Dieu, 1 parvis Notre Dame, 75004, Paris, France; UMR S 1124, Faculté de Médecine, Université Paris Descartes, Paris, France
| |
Collapse
|
33
|
Nikulshina MS, Blanchard P, Mozhaev A, Lancelot C, Griboval-Constant A, Fournier M, Payen E, Mentré O, Briois V, Nikulshin PA, Lamonier C. Molecular approach to prepare mixed MoW alumina supported hydrotreatment catalysts using H4SiMonW12−nO40 heteropolyacids. Catal Sci Technol 2018. [DOI: 10.1039/c8cy00672e] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Higher catalytic conversions and different selectivity ratios are explained by the formation of the mixed (MoW)S2 active phase when using mixed MoW heteropolyacid as starting material.
Collapse
Affiliation(s)
| | | | - A. Mozhaev
- Samara State Technical University
- Samara
- Russia
| | - C. Lancelot
- Univ. Lille
- CNRS
- Centrale Lille
- ENSCL
- Univ. Artois
| | | | - M. Fournier
- Univ. Lille
- CNRS
- Centrale Lille
- ENSCL
- Univ. Artois
| | - E. Payen
- Univ. Lille
- CNRS
- Centrale Lille
- ENSCL
- Univ. Artois
| | - O. Mentré
- Univ. Lille
- CNRS
- Centrale Lille
- ENSCL
- Univ. Artois
| | - V. Briois
- Synchrotron SOLEIL
- CNRS-UR1
- Gif-sur-Yvette
- France
| | | | - C. Lamonier
- Univ. Lille
- CNRS
- Centrale Lille
- ENSCL
- Univ. Artois
| |
Collapse
|
34
|
Collette C, Boothroyd L, Pomey M, Fournier M, Grégoire A, Ganache I, Lambert L, de Guise M. DECISION-MAKING AT THE TIME OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR REPLACEMENT: ACTIVELY INTEGRATING THE PATIENT’S PERSPECTIVE. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
35
|
Fournier M, Monin A, Ferrari C, Baumann PS, Conus P, Do K. Implication of the glutamate-cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis. NPJ Schizophr 2017; 3:31. [PMID: 28924227 PMCID: PMC5603608 DOI: 10.1038/s41537-017-0035-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 08/22/2017] [Accepted: 08/23/2017] [Indexed: 12/30/2022]
Abstract
xCT is the specific chain of the cystine/glutamate antiporter, which is widely reported to support anti-oxidant defenses in vivo. xCT is therefore at the crossroads between two processes that are involved in schizophrenia: oxidative stress and glutamatergic neurotransmission. But data from human studies implicating xCT in the illness and clarifying the upstream mechanisms of xCT imbalance are still scarce. Low glutathione (GSH) levels and genetic risk in GCLC (Glutamate–Cysteine Ligase Catalytic subunit), the gene of limiting synthesizing enzyme for GSH, are both associated with schizophrenia. In the present study, we aimed at determining if xCT regulation by the redox system is involved in schizophrenia pathophysiology. We assessed whether modulating GCLC expression impact on xCT expression and activity (i) in fibroblasts from patients and controls with different GCLC genotypes which are known to affect GCLC regulation and GSH levels; (ii) in rat brain glial cells, i.e., astrocytes and oligodendrocytes, with a knock-down of GCLC. Our results highlight that decreased GCLC expression leads to an upregulation of xCT levels in patients’ fibroblasts as well as in astrocytes. These results support the implication of xCT dysregulation in illness pathophysiology and further indicate that it can result from redox changes. Additionally, we showed that these anomalies may already take place at early stages of psychosis and be more prominent in a subgroup of patients with GCLC high-risk genotypes. These data add to the existing evidence identifying the inflammatory/redox systems as important targets to treat schizophrenia already at early stages. Deficit of antioxidant synthesis in schizophrenia leads to oxidative stress and changes in neurotransmitter transporter. Led by Kim Do, a team of researchers from Lausanne University in Switzerland investigated the role of the cell-surface transport protein xCT in schizophrenia. They found that an enzyme responsible for antioxidant production is disturbed in patients. This leads to decreased antioxidant levels and consequently to oxidative stress—i.e. the accumulation of reactive oxygen molecules, damaging the cells component and impairing cell functioning—which in turn affects the functioning of the antioxidant pathway, including xCT. xCT, which exports the neurotransmitter glutamate, is thus overproduced in schizophrenia. The resulting increase of neurotransmitter activity, alongside the increase in oxidative stress, is thought to play a major role in the pathophysiology of schizophrenia, including at early stages of the disease.
Collapse
Affiliation(s)
- M Fournier
- Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital, Switzerland, Switzerland
| | - A Monin
- Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital, Switzerland, Switzerland
| | - C Ferrari
- Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital, Switzerland, Switzerland
| | - P S Baumann
- Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital, Switzerland, Switzerland.,Department of Psychiatry, Service of general psychiatry, Lausanne University Hospital, Switzerland, Switzerland
| | - P Conus
- Department of Psychiatry, Service of general psychiatry, Lausanne University Hospital, Switzerland, Switzerland
| | - K Do
- Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital, Switzerland, Switzerland.
| |
Collapse
|
36
|
Nikulshina MS, Mozhaev AV, Minaev PP, Fournier M, Lancelot C, Blanchard P, Payen E, Lamonier C, Nikulshin PA. Trimetallic NiMoW/Al2O3 hydrotreating catalyst based on H4SiMo3W9O40 mixed heteropoly acid. RUSS J APPL CHEM+ 2017. [DOI: 10.1134/s1070427217070151] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
37
|
Fournier M. Cinétique des réactions primaires en électrolyse étudiée à l'oscillographe cathodique par la méthode polarographique. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/195249s2c183] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
38
|
Taouk B, Ghoussoub D, Bennani A, Crusson E, Rigole M, Aboukais A, Decressain R, Fournier M, Guelton M. Characterization by 51V solid state NMR of vanadium in dehydrated H4PVMo11O40 and Na1.5H2.5PVMo11O40 catalysts. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1992890435] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
39
|
Rabia C, Bettahar MM, Launay S, Hervé G, Fournier M. Préparation et caractérisation de l’acide 1-vanado-11-molybdophosphorique et de ses sels alcalins. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1995921442] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
40
|
Chelighem B, Launay S, Essayem N, Coudurier G, Fournier M. Préparation de phosphomolybdates (tungstates) par réaction à l’état solide et par précipitation : réactivité dans la conversion du propane-2-ol. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1997941831] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
41
|
Fournier M, Allavena M, Potier A. Calcul théorique des constantes de force de l’ion H3O+ et comparaison avec les résultats expérimentaux. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1972691520] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
42
|
Calmet D, Ameon R, Bombard A, Brun S, Byrde F, Chen J, Duda JM, Forte M, Fournier M, Fronka A, Haug T, Herranz M, Husain A, Jerome S, Jiranek M, Judge S, Kim SB, Kwakman P, Loyen J, LLaurado M, Michel R, Porterfield D, Ratsirahonana A, Richards A, Rovenska K, Sanada T, Schuler C, Thomas L, Tokonami S, Tsapalov A, Yamada T. INTERNATIONAL STANDARDS ON FOOD AND ENVIRONMENTAL RADIOACTIVITY MEASUREMENT FOR RADIOLOGICAL PROTECTION: STATUS AND PERSPECTIVES. Radiat Prot Dosimetry 2017; 173:55-62. [PMID: 27885091 DOI: 10.1093/rpd/ncw342] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Radiological protection is a matter of concern for members of the public and thus national authorities are more likely to trust the quality of radioactivity data provided by accredited laboratories using common standards. Normative approach based on international standards aims to ensure the accuracy or validity of the test result through calibrations and measurements traceable to the International System of Units. This approach guarantees that radioactivity test results on the same types of samples are comparable over time and space as well as between different testing laboratories. Today, testing laboratories involved in radioactivity measurement have a set of more than 150 international standards to help them perform their work. Most of them are published by the International Standardization Organization (ISO) and the International Electrotechnical Commission (IEC). This paper reviews the most essential ISO standards that give guidance to testing laboratories at different stages from sampling planning to the transmission of the test report to their customers, summarizes recent activities and achievements and present the perspectives on new standards under development by the ISO Working Groups dealing with radioactivity measurement in connection with radiological protection.
Collapse
Affiliation(s)
- D Calmet
- Commissariat à l'énergie atomique et aux énergies alternatives, Direction Protection Sûreté Nucléaire, 92265 Fontenay aux Roses Cedex, France
| | - R Ameon
- ALGADE, 1 Avenue du Brugeaud - BP 46 - 87250 Bessines sur Gartempe, France
| | - A Bombard
- TrisKem International, ZAC de l'Eperon, 3 rue des Champs Géons, 35170 Bruz, France
| | - S Brun
- CEA/Saclay, Service de protection contre les rayonnements, 91191 Gif-sur-Yvette Cedex, France
| | - F Byrde
- Gruppe Radioaktivität, Eidgenössisches Departement für Verteidigung, Bundesamt für Bevölkerungsschutz, 3700 Spiez, Switzerland
| | - J Chen
- Radiation Protection Bureau, Health Canada, 775 Brookfield Road, Ottawa K1A 1C1, Ontario, Canada
| | - J-M Duda
- CEA/Valduc, Service de protection contre les rayonnements, 21120 Is-sur-Tille, France
| | - M Forte
- ARPA Lombardia, Centro Regionale di Radioprotezione, Via Juvara 22, 20129 Milano, Italy
| | - M Fournier
- Autorité de sûreté nucléaire, 15 rue Louis Lejeune, CS 70013, 92541 Montrouge Cedex, France
| | - A Fronka
- National Radiation Protection Institute, Bartoškova 28, Praha 4 140 00, Czech Republic
| | - T Haug
- Eberhard Karls-University of Tuebingen, Isotope lab & radiation protection, Auf der Morgenstelle 24, 72076 Tübingen, Germany
| | - M Herranz
- Department of Nuclear Engineering and Fluid Mechanics, alda Urquijo s/n, 48013 Bilbao, Spain
| | - A Husain
- Kinectrics Inc. 800 Kipling Avenue, Unit 2 Toronto, Ontario M8Z 5G5, Canada
| | - S Jerome
- The National Physical Laboratory, Queens Road, Teddington, Middlesex TW11 0LW, UK
| | - M Jiranek
- Faculty of Civil Engineering, Czech Technical University, Tha´kurova 7, 166 29 Praha 6 , Czech Republic
| | - S Judge
- The National Physical Laboratory, Queens Road, Teddington, Middlesex TW11 0LW, UK
| | - S B Kim
- Environmental Technologies Branch, Chalk River Laboratories, Stn 51A, Canada
| | - P Kwakman
- RIVM, Centre for Environmental Safety and Security, Department for Measuring and Monitoring. PO Box 1, 3720 BA Bilthoven, The Netherlands
| | - J Loyen
- Autorité de sûreté nucléaire, 15 rue Louis Lejeune, CS 70013, 92541 Montrouge Cedex, France
| | - M LLaurado
- Departamento Quimica Analytica, Laboratori de Radiologia Ambiental, Facultat de Quimica-Universitat de Barcelona, Marti i Franques, 1-11, 08028 Barcelona , Spain
| | - R Michel
- Leibniz Universität, Institut für Radioökologie und Strahlenschutz, Wilh.-Henze-Weg 14; D-31303 Burgdorf, Germany
| | - D Porterfield
- Los Alamos National Laboratory, PO Box 1663, MS G740, Los Alamos, NM 87545, USA
| | - A Ratsirahonana
- CEA/Saclay, Service de protection contre les rayonnements, 91191 Gif-sur-Yvette Cedex, France
| | - A Richards
- BSI, 389 Chiswick High Road, London W4 4AL, UK
| | - K Rovenska
- National Radiation Protection Institute, Bartoskova 28, Prague 4, Czech Republic
| | - T Sanada
- Hokkaido University of Science, Department of Radiological Technology, Faculty of Health Sciences, Sapporo, Japan
| | - C Schuler
- Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
| | - L Thomas
- AFNOR, 11 rue Francis de Pressensé, 93571 La Plaine Saint-Denis cedex, France
| | - S Tokonami
- Department of Radiation Physics, Institute of Radiation Emergency Medicine, Hirosaki University, Hirosaki City, Aomori 036-8564 , Japan
| | - A Tsapalov
- Laboratory of Radiation Safety in Building, Research Institute of Building Physics, Russian Academy of Architecture and Building Science, Moscow, Russia
| | - T Yamada
- Japan Radioisotope Association, 28-45, Honkomagome 2 , Bunkyo-ku, Tokyo1138941, Japan
| |
Collapse
|
43
|
Baglan N, Kim SB, Cossonnet C, Croudace IW, Fournier M, Galeriu D, Warwick PE, Momoshima N, Ansoborlo E. Organically Bound Tritium Analysis in Environmental Samples. Fusion Science and Technology 2017. [DOI: 10.13182/fst14-t3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Baglan
- CEA/DAM/DIF – F91297 Arpajon – France
| | - S. B. Kim
- AECL, Chalk River Laboratories, Chalk River, Ontario, Canada, K0J1J0
| | - C. Cossonnet
- IRSN/PRP-ENV/STEME/LMRE, Bat 501 - Bois des Rames, 91400 Orsay, France
| | - I. W. Croudace
- GAU-Radioanalytical, University of Southampton, NOC, European Way, SO14 3ZH, UK
| | - M. Fournier
- IRSN/DG/DMQ, BP17, 92262 Fontenay aux Roses Cedex – France
| | - D. Galeriu
- IFIN-HH, “Horia Hulubei“ InstPhys & NuclEngn, RO-077125 Bucharest, Romania
| | - P. E. Warwick
- GAU-Radioanalytical, University of Southampton, NOC, European Way, SO14 3ZH, UK
| | - N. Momoshima
- Kyushu Univ, Radioisotope Ctr, Higashi Ku, Fukuoka 8128581, Japan
| | - E. Ansoborlo
- CEA/DEN/DRCP/CETAMA - BP17171 – 30207 Bagnols-sur-Cèze – France
| |
Collapse
|
44
|
Tunon de Lara C, Bonnet F, Debled M, Lafon D, Breton-Callu C, Rarouk-Simonet E, Fournier M, Petit A, Bubien V, Quenel-Tueux N, Lagarde P, Longy M, Macgrogan G, Sevenet N. Abstract P5-16-23: Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Neoadjuvant chemotherapy (NAC) is proposed in case of locally advanced breast cancer (LABC) to improve breast conservative treatment (BCT). In the case of germline BRCA mutated (gBRCAm) patients, risk-reducing prophylactic surgical strategies in France are mastectomy for pre-symptomatic. On the other hand, BCT is proposed to all patients after NAC according to clinical response, regardless their gBRCAm status. Moreover, in the case of BRCA mutation, local recurrence risk at 15 years is higher in the BCT group (23%) vs mastectomy (5%) (Pierce 2010). The aim of this retrospective one-institution analysis is to evaluate if the knowledge of gBRCAm status impact surgical decision.
Patients and methods
All patients who underwent BRCA genetic testing during NAC for ≥ 3cm breast cancer between 2012 and 2015 were included. BRCA testing was decided with each patient based on age, familial history of breast or ovarian cancer and histological characteristics of the tumor. Rapid germline BRCA mutation screening was performed through targeted next generation sequencing with a 25-genes panel including full coding sequence of BRCA1 & 2. Deleterious mutations were detected using MiSeq reporter and confirmed by Sanger sequencing before giving the results to the clinical geneticist, and finally used for the choice of surgical strategy. At the end of NAC (6 three-weeks cycles in our center), a shared-decision making for surgical procedure was performed, based on pre and post-NAC clinical and radiological features, and results of the genetic testing.
Results
A total of 25 patients (including three with bilateral cancer) were tested during NAC: mean age 38 years (26-64); mean clinical size 46 mm (20-130mm); histological types: triple negative (n=14), HER-2 positive (n=7), luminal (n=7). A germline BRCA mutation was detected in 10 patients (40%) : 8 BRCA1 and 2 BRCA2, including 8 patients among the 14 patients with a Manchester score > 20 (6 BRCA1 & 2 BRCA2). Two patients were secondarily excluded (one being metastatic and one died during NAC), one of them having a gBRCAm status. All the 23 patients evaluable for the surgical procedure after NAC could be eligible for a BCT. All the 9 patients with gBRCAm status choose mastectomy in the shared-decision making procedure while a BCT was performed in 12 of the 14 remaining patients without BRCA mutation.
Discussion
In this highly selected subgroup of patients, gBRCAm rate is higher (40%) than the usual rate for BRCA testing (17% in our center). Regarding the rationale for BCT or mastectomy procedure in LABC or pre-symptomatic gBRCAm patients, the duration of NAC allows rapid germline BRCA screening that looks very useful considering the high incidence of mutation we observed and the impact on surgical final decision. Furthermore, in the group of high Manchester score (>20), patients without BRCA mutation harbored incidental mutation, currently under analysis, especially on other genes involved in hereditary breast cancer, that could also be used as a compelling argument for mastectomy.
Citation Format: Tunon de Lara C, Bonnet F, Debled M, Lafon D, Breton-Callu C, Rarouk-Simonet E, Fournier M, Petit A, Bubien V, Quenel-Tueux N, Lagarde P, Longy M, Macgrogan G, Sevenet N. Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-23.
Collapse
Affiliation(s)
| | - F Bonnet
- Institut Bergonie, Bordeaux, France
| | - M Debled
- Institut Bergonie, Bordeaux, France
| | - D Lafon
- Institut Bergonie, Bordeaux, France
| | | | | | | | - A Petit
- Institut Bergonie, Bordeaux, France
| | - V Bubien
- Institut Bergonie, Bordeaux, France
| | | | | | - M Longy
- Institut Bergonie, Bordeaux, France
| | | | | |
Collapse
|
45
|
Caza F, Betoulle S, Auffret M, Brousseau P, Fournier M, St-Pierre Y. Comparative Sequence Analysis of Hsp70 Gene from Mytilus Edulis Desolationis and Aulacomya ater of the Kerguelen Islands. J Xenobiot 2016; 6:6721. [PMID: 30701056 PMCID: PMC6324491 DOI: 10.4081/xeno.2016.6721] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- F Caza
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - S Betoulle
- Université Reims Champagne-Ardenne, UMR-I 02 SEBIO Stress environnementaux et Biosurveillance des milieux aquatiques, Reims, France
| | - M Auffret
- Laboratoire des Sciences de l'Environnement Marin, UMR CNRS 6539-LEMAR, Plouzane, France
| | - P Brousseau
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - M Fournier
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - Y St-Pierre
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| |
Collapse
|
46
|
Fournier M, Bourriquen G, Lamaze FC, Côté MC, Fournier É, Joly-Beauparlant C, Caron V, Gobeil S, Droit A, Bilodeau S. FOXA and master transcription factors recruit Mediator and Cohesin to the core transcriptional regulatory circuitry of cancer cells. Sci Rep 2016; 6:34962. [PMID: 27739523 PMCID: PMC5064413 DOI: 10.1038/srep34962] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 09/20/2016] [Indexed: 01/07/2023] Open
Abstract
Controlling the transcriptional program is essential to maintain the identity and the biological functions of a cell. The Mediator and Cohesin complexes have been established as central cofactors controlling the transcriptional program in normal cells. However, the distribution, recruitment and importance of these complexes in cancer cells have not been fully investigated. Here we show that FOXA and master transcription factors are part of the core transcriptional regulatory circuitry of cancer cells and are essential to recruit M ediator and Cohesin. Indeed, Mediator and Cohesin occupied the enhancer and promoter regions of actively transcribed genes and maintained the proliferation and colony forming potential. Through integration of publically available ChIP-Seq datasets, we predicted the core transcriptional regulatory circuitry of each cancer cell. Unexpectedly, for all cells investigated, the pioneer transcription factors FOXA1 and/or FOXA2 were identified in addition to cell-specific master transcription factors. Loss of both types of transcription factors phenocopied the loss of Mediator and Cohesin. Lastly, the master and pioneer transcription factors were essential to recruit Mediator and Cohesin to regulatory regions of actively transcribed genes. Our study proposes that maintenance of the cancer cell state is dependent on recruitment of Mediator and Cohesin through FOXA and master transcription factors.
Collapse
Affiliation(s)
- Michèle Fournier
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | - Gaëlle Bourriquen
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | - Fabien C. Lamaze
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | - Maxime C. Côté
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | - Éric Fournier
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | | | - Vicky Caron
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
| | - Stéphane Gobeil
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
- Département de médecine moléculaire, Faculté de Médecine, Université Laval, Québec, Canada
| | - Arnaud Droit
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
- Département de médecine moléculaire, Faculté de Médecine, Université Laval, Québec, Canada
| | - Steve Bilodeau
- Centre de Recherche sur le Cancer de l’Université Laval, Québec, Canada
- Centre de recherche du CHU de Québec – Université Laval, Québec, Canada
- Département de biologie moléculaire, biochimie médicale et pathologie, Faculté de Médecine, Université Laval, Québec, Canada
| |
Collapse
|
47
|
Fournier M, d'Arripe-Longueville F, Radel R. Testing the effect of text messaging cues to promote physical activity habits: a worksite-based exploratory intervention. Scand J Med Sci Sports 2016; 27:1157-1165. [PMID: 27540899 DOI: 10.1111/sms.12730] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/16/2016] [Indexed: 11/30/2022]
Abstract
This study aims to test the efficacy of text messaging cues (SMS) to promote physical activity (PA) habit formation in the workplace. Employees (N = 49; 28 females and 21 males, Mage = 47.5 ± 8.29 years) were randomized into two parallel groups: a PA group enrolled in a 28-week supervised PA program and a PA+SMS group enrolled in the same PA program with text messaging cues received before their PA sessions. The exercise habit was assessed every week from self-reports on an online application. PA maintenance and several physical fitness measures were also assessed prior to and after the intervention to evaluate its general impact. Mixed model analysis of the 603 observations indicated a small but significant effect of the SMS cues on the speed at which participants engaged in PA behaviors, as the significant interaction effect revealed that the slope of the exercise habit over time was slightly steeper in the PA+SMS group (B = 0.0462, P = 0.0001) than in the PA group (B = 0.0216, P = 0.01). SMS delivery had a marginal effect on the maintenance of PA behaviors 1 year after the intervention. The results suggest that text messaging can help to form PA habits at the workplace and might facilitate long-term maintenance of PA behaviors.
Collapse
Affiliation(s)
- M Fournier
- LAMHESS EA 6309, University of Nice Sophia Antipolis and University of Toulon, Nice, France
| | - F d'Arripe-Longueville
- LAMHESS EA 6309, University of Nice Sophia Antipolis and University of Toulon, Nice, France
| | - R Radel
- LAMHESS EA 6309, University of Nice Sophia Antipolis and University of Toulon, Nice, France
| |
Collapse
|
48
|
Baumann PS, Griffa A, Fournier M, Golay P, Ferrari C, Alameda L, Cuenod M, Thiran JP, Hagmann P, Do KQ, Conus P. Impaired fornix-hippocampus integrity is linked to peripheral glutathione peroxidase in early psychosis. Transl Psychiatry 2016; 6:e859. [PMID: 27459724 PMCID: PMC5545707 DOI: 10.1038/tp.2016.117] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Revised: 03/17/2016] [Accepted: 04/15/2016] [Indexed: 12/19/2022] Open
Abstract
Several lines of evidence implicate the fornix-hippocampus circuit in schizophrenia. In early-phase psychosis, this circuit has not been extensively investigated and the underlying mechanisms affecting the circuit are unknown. The hippocampus and fornix are vulnerable to oxidative stress at peripuberty in a glutathione (GSH)-deficient animal model. The purposes of the current study were to assess the integrity of the fornix-hippocampus circuit in early-psychosis patients (EP), and to study its relationship with peripheral redox markers. Diffusion spectrum imaging and T1-weighted magnetic resonance imaging (MRI) were used to assess the fornix and hippocampus in 42 EP patients compared with 42 gender- and age-matched healthy controls. Generalized fractional anisotropy (gFA) and volumetric properties were used to measure fornix and hippocampal integrity, respectively. Correlation analysis was used to quantify the relationship of gFA in the fornix and hippocampal volume, with blood GSH levels and glutathione peroxidase (GPx) activity. Patients compared with controls exhibited lower gFA in the fornix as well as smaller volume in the hippocampus. In EP, but not in controls, smaller hippocampal volume was associated with high GPx activity. Disruption of the fornix-hippocampus circuit is already present in the early stages of psychosis. Higher blood GPx activity is associated with smaller hippocampal volume, which may support a role of oxidative stress in disease mechanisms.
Collapse
Affiliation(s)
- P S Baumann
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
- Department of Psychiatry, Service of General Psychiatry, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - A Griffa
- Signal Processing Laboratory (LTS5), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - M Fournier
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - P Golay
- Department of Psychiatry, Service of General Psychiatry, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), Lausanne, Switzerland
- Service of Community Psychiatry, Department of Psychiatry, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - C Ferrari
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - L Alameda
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
- Department of Psychiatry, Service of General Psychiatry, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - M Cuenod
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - J-P Thiran
- Signal Processing Laboratory (LTS5), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - P Hagmann
- Signal Processing Laboratory (LTS5), Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - K Q Do
- Department of Psychiatry, Unit for Research in Schizophrenia, Center for Psychiatric Neuroscience, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland
| | - P Conus
- Department of Psychiatry, Service of General Psychiatry, Centre Hospitalier Universitaire Vaudois, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| |
Collapse
|
49
|
Oton CJ, Manganelli C, Bontempi F, Fournier M, Fowler D, Kopp C. Silicon photonic waveguide metrology using Mach-Zehnder interferometers. Opt Express 2016; 24:6265-6270. [PMID: 27136819 DOI: 10.1364/oe.24.006265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We propose a procedure for characterizing fabrication deviations within a chip and among different chips in a wafer in silicon photonics technology. In particular, independent measurements of SOI thickness and waveguide width deviations can be mapped through the wafer, allowing a precise and non-destructive characterization of how these variations are distributed along the surface of the wafer. These deviations are critical for most wavelength-dependent integrated devices, like microring resonators, filters, etc. We also show that the technique allows for the characterization of proximity effects.
Collapse
|
50
|
Côté C, Brousseau-Fournier C, Pharand P, Gagné F, Brousseau P, Fournier M. Immunotoxicity of Benzothiazole on Mytilus Edulis Following In Vitro Exposure of Hemocytes. J Xenobiot 2015; 5:5771. [PMID: 30701043 PMCID: PMC6324468 DOI: 10.4081/xeno.2015.5771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Affiliation(s)
- C Côté
- Parc de la rivière Mitis, Ste-Flavie, Canada.,ISMER - Université du Québec à Rimouski, Rimouski, Canada
| | - C Brousseau-Fournier
- Parc de la rivière Mitis, Ste-Flavie, Canada.,ISMER - Université du Québec à Rimouski, Rimouski, Canada
| | - P Pharand
- Parc de la rivière Mitis, Ste-Flavie, Canada.,ISMER - Université du Québec à Rimouski, Rimouski, Canada
| | - F Gagné
- Environnement Canada, Montréal, Québec, Canada
| | - P Brousseau
- Parc de la rivière Mitis, Ste-Flavie, Canada.,ISMER - Université du Québec à Rimouski, Rimouski, Canada
| | - M Fournier
- Parc de la rivière Mitis, Ste-Flavie, Canada.,ISMER - Université du Québec à Rimouski, Rimouski, Canada
| |
Collapse
|